| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57563
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 |
| filingDate |
2018-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa357a46141660028c775b61cbd5565d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e3616ad577827d94d6c119d9479a637
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de2ce9a623b4dc379e6425f2ed9d4431
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4305c0b17ebb16bbc2b31c45770aac8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4744d44f2028826732a9ccc516c68956 |
| publicationDate |
2019-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CY-1121032-T1 |
| titleOfInvention |
EXENDINI DERIVATIVES-4 AS SELECTIVE MATCHERS GLYCAGONE RECEPTORS |
| abstract |
The present invention relates to glucagon receptor agonists and their medical use, for example in the treatment of severe hypoglycaemia. Exendin-4 analogs are provided which actively and selectively activate the glucagon receptor and show higher solubility at near neutral pH as well as enhanced chemical stability in solution compared to natural glucagon. The analogues have the artificial amino acid 4-thiazolylalanine at position 1. This leads to a higher selectivity for the glucagon receptor than the GLP1 receptor when identical compounds differing only at position 1 (Tza at position 1 instead of His). The present invention provides highly selective glucagon receptor agonists. |
| priorityDate |
2014-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |